학술논문
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Document Type
Article
Author
Rosenfeld, Margaret; Starner, Timothy; Retsch-Bogart, George; Chmiel, James; Orenstein, David; Milla, Carlos; Rubenstein, Ronald; Walker, Seth; Cornell, Alexandra; Asfour, Fadi; Black, Philip; Colombo, John; Froh, Deborah; McColley, Susanna; Ruiz, Fadel; Quintero, Diana; Casey, Alicia; Mueller, Gary; Flume, Patrick; Livingston, Floyd; Rock, Michael; O'Sullivan, Brian; Schmidt, Howard; Lahiri, Thomas; McNamara, John; Chidekel, Aaron; Sass, Laura; Keens, Thomas; Schaeffer, David; Solomon, Melinda; Chilvers, Mark; Lands, Larry; Junge, Sibylle; Griese, Matthias; Staab, Doris; Pressler, Tacjana; van Koningsburggen-Rietschel, Silke; Naehrlich, Lutz; Reid, Alastair; Balfour-Lynn, Ian; Urquhart, Don; Lee, Timothy; Munck, Anne; Gaudelus, Isabelle Sermet; De Boeck, Christiane; Reix, Philippe; Malfroot, Anne; Bui, Stéphanie; Selvadurai, Hiranjan; Robinson, Philip; Wainwright, Claire; Clements, Barry; Hilton, Jodi; Hjelte, Lena; Ratjen, Felix; Hug, Christopher; Marigowda, Gautham; Tian, Simon; Huang, Xiaohong; Stanojevic, Sanja; Milla, Carlos E; Robinson, Paul D; Waltz, David; Davies, Jane C
Source
In The Lancet Respiratory Medicine July 2017 5(7):557-567
Subject
Language
ISSN
2213-2600